论文部分内容阅读
目的:观察霉酚酸酯、复方甘草酸苷、拉米夫定联合治疗乙型肝炎病毒相关性肾炎的疗效及安全性。方法:选取2001年6月至2006年6月我院住院患者23例,均符合乙型肝炎病毒相关性肾炎和肾病综合征诊断标准。给予霉酚酸酯1.5g/d、复方甘草酸苷0.1g/d及拉米夫定0.1g/d,治疗6个月,每2～4周复查尿蛋白定量、血清白蛋白、肝肾功能、HBV-DNA定量、血常规。结果:治疗后8例完全缓解,11例部分缓解,4例无效,所有患者治疗过程中未出现肝、肾损害和骨髓抑制等不良反应。结论:霉酚酸酯联合复方甘草酸苷、拉米夫定治疗乙型肝炎病毒相关性肾炎有效且安全。
Objective: To observe the efficacy and safety of mycophenolate mofetil, compound glycyrrhizin and lamivudine in the treatment of hepatitis B virus-associated nephritis. Methods: Twenty-three inpatients in our hospital from June 2001 to June 2006 were selected, which all met the diagnostic criteria of hepatitis B virus-associated nephritis and nephrotic syndrome. Mycophenolate mofetil 1.5g / d, compound glycyrrhizin 0.1g / d and lamivudine 0.1g / d were given for 6 months. Urinary protein, serum albumin, liver and kidney function were evaluated every 2 ~ 4 weeks , HBV-DNA quantification, blood routine. Results: After treatment, 8 cases were completely relieved, 11 cases were partially relieved, 4 cases were ineffective. All the patients had no adverse reactions such as liver and kidney damage and myelosuppression during the course of treatment. Conclusion: Mycophenolate mofetil and compound glycyrrhizin and lamivudine are effective and safe in treating hepatitis B virus associated glomerulonephritis.